TITLE

Morphine Oral - Elan Corporation: Avinzaâ„¢

PUB. DATE
June 2002
SOURCE
Drugs in R&D;2002, Vol. 3 Issue 3, p208
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Adis Comments Elan Corporation is developing an oral, once daily, controlled-release formulation of morphine sulphate (formerly called Morphelanâ„¢) for use in pain management therapy. Elan Corporation has been granted marketing approval by the FDA for Avinzaâ„¢ (morphine sulphate extended-release) capsules for chronic pain in oncology and HIV-positive patients. Avinzaâ„¢ was approved for once daily treatment of chronic, moderate to severe pain in patients who require continuous pain management for an extended period of time. Avinzaâ„¢ was investigated in clinical trials in 560 patients with chronic moderate to severe pain resulting from both malignant and non-malignant causes. The proprietary formulation of morphine consists of two components: an immediate-release component that provides fast onset and rapid achievement of the plateau of plasma morphine concentrations, and an extended-release component that maintains plasma concentrations of morphine throughout the 24-h interval. The rationale behind the once-daily formulation of Avinzaâ„¢ is to create and maintain the plateau concentration of morphine after reaching steady-state plasma morphine level. Avinzaâ„¢ will be available as a prescription medicine in 30, 60, 90 and 120mg capsules. It can be taken with or without food. Labeling of Avinzaâ„¢ warns against chewing, crushing or dissolving the capsule due to the risk of absorption of potentially fatal dose of morphine. Elan Corporation has licensed the morphine oral formulation to Ligand Pharmaceuticals with exclusive rights in the USA and Canada for the treatment of chronic pain in cancer and HIV patients. Both companies have also granted each other co-promotional rights to the USA, Canada and Europe. Under the agreement, Ligand Pharmaceuticals pays Elan Corporation upfront license fees on closing and milestone payments upon the occurrence of certain events. Payments of the milestones may be either in cash or in shares of Ligand common stock. In connection with the NDA submission, Ligand Pharmaceuticals paid Elan Corporation 367 183 shares of Ligand common stock, with a total value of US$4 million. The approval of Avinzaâ„¢ triggers a US$5 million milestone payment from Ligand to Elan in the form of 302 554 shares of common stock. Ligand Pharmaceuticals is planning to launch Avinzaâ„¢ early in Q2 of 2002. Morphine oral formulation was licensed exclusively worldwide to Targon, a joint venture between Cytogen and Elan Corporation. However, the joint venture was dissolved, and the rights to the drug were retained by Elan Corporation.
ACCESSION #
6832329

 

Related Articles

  • Elan's New Drug Reduces Severity of Cervical Dystonia.  // Worldwide Biotech;Dec99, Vol. 11 Issue 12, p2 

    Looks at the results of the studies conducted by Elan Pharmaceuticals Inc. of South San Francisco, California on the drug treating cervical dystonia. Evaluation of Elan's Botulinum Toxin Type B Injectable Solution; Phases of the clinical trial; Effectiveness.

  • P & T PORTFOLIO.  // Drug Topics;7/15/2002, Vol. 146 Issue 14, pHSE20 

    Provides information on Avinza, or morphine sulfate extended-release capsules, from Elan Corp. for treatment of moderate to severe pain. Pharmacology; Efficacy; Contraindications; Side effects.

  • Clinic Roundup.  // BioWorld Today;8/31/2012, Vol. 23 Issue 170, p8 

    The article reports on the initiation of a Phase II trial of oral ELND005 by Elan Corp. plc, the licensing partner of Transition Therapeutics Inc., as an adjunctive maintenance treatment of bipolar I disorder patients to delay the time to occurrence of mood episodes.

  • Call for Elan to publish Alzheimer's trial details. Bishop, Glenda M.; Robinson, Stephen R.; Smith, Mark A.; Perry, George; Atwood, Craig S. // Nature;4/18/2002, Vol. 416 Issue 6882, p677 

    Focuses on the request of the authors to Elan Pharmaceuticals to publish the details of the trial of the treatment of Alzheimer's disease. Release of Elan of details of their medical condition; Withdrawal of Elan of AN-1792 vaccine from human trials; Lack of obligation of Elan to report the...

  • Beware of morphine overdoses.  // Drug Topics;10/20/2003, Vol. 147 Issue 20, p8 

    Highlights the warning issued by pharmaceutical firm Elan Pharmaceuticals about the serious adverse events and possible deaths resulting from accidental overdose of high concentration morphine oral solutions.

  • Elan and Wyeth to take Alzheimer's drug to phase III.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p6 

    The article reports on the plan of Elan Corp. and Wyeth Pharmaceuticals to initiate a phase III clinical program for bapineuzumab, a humanized monoclonal antibody which is used to treat patients with mild to moderate Alzheimer's disease. According to the author, the move was based on a scheduled...

  • Isis Starts Clinical Trials for Hepatitis C Drug. Webb, Marion // San Diego Business Journal;4/1/2002, Vol. 23 Issue 13, p10 

    Reports the clinical trials for an experimental hepatitis C drug by Isis Pharmaceuticals Inc. and Elan Corp. in Carlsbad, California. Evaluation on the safety and tolerance of the compound; Details of the drug administration on patients; Views of F. Andrew Dorr, vice president of Isis on drug...

  • J&J Deal Lifts Overhang on Elan Stock; Investors Cautious. Sheridan, Cormac // BioWorld International;7/8/2009, Vol. 14 Issue 27, p1 

    The article reports on the U.S.$1.5 billion partnership deal signed by Elan Corp. PLC with Johnson & Johnson covering its Alzheimer's disease immunotherapy program. The growth of Elan's drug was hampered by reports of progressive multifocal leukoencephalopathy (PML) occuring in multiple...

  • In Brief. L.F.; A.B.; J.F. // Nature Biotechnology;Apr2002, Vol. 20 Issue 4, p327 

    Reports on various biotechnology business and regulatory news as of April 2002. Elan Corp.'s termination of clinical trials of its experimental vaccine for the treatment of Alzheimer's disease; Naming of Lester Crawford as deputy commissioner of the U.S. Food and Drug Administration;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics